170 related articles for article (PubMed ID: 17083124)
1. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
Krishnan S; Rana V; Janjan NA; Abbruzzese JL; Gould MS; Das P; Delclos ME; Palla S; Guha S; Varadhachary G; Evans DB; Wolff RA; Crane CH
Cancer; 2006 Dec; 107(11):2589-96. PubMed ID: 17083124
[TBL] [Abstract][Full Text] [Related]
2. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
[TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.
Krishnan S; Rana V; Janjan NA; Varadhachary GR; Abbruzzese JL; Das P; Delclos ME; Gould MS; Evans DB; Wolff RA; Crane CH
Cancer; 2007 Jul; 110(1):47-55. PubMed ID: 17538975
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
Gillmore R; Laurence V; Raouf S; Tobias J; Blackman G; Meyer T; Goodchild K; Collis C; Bridgewater J
Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):564-9. PubMed ID: 20605709
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
Desai S; Ben-Josef E; Griffith KA; Simeone D; Greenson JK; Francis IR; Hampton J; Colletti L; Chang AE; Lawrence TS; Zalupski MM
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1450-5. PubMed ID: 19409732
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
Hudson E; Hurt C; Mort D; Brewster AE; Iqbal N; Joseph G; Crosby TD; Mukherjee S
Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):27-35. PubMed ID: 19896352
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Nanda RH; El-Rayes B; Maithel SK; Landry J
J Surg Oncol; 2015 Jun; 111(8):1028-34. PubMed ID: 26073887
[TBL] [Abstract][Full Text] [Related]
11. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer.
Kim HS; Yi SY; Jun HJ; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Choi DW; Choi SH; Heo JS; Park YS; Lim HY; Kang WK; Park HC; Lim DH; Park JO
Anticancer Drugs; 2010 Jan; 21(1):107-12. PubMed ID: 19829097
[TBL] [Abstract][Full Text] [Related]
12. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study.
Wilkowski R; Boeck S; Ostermaier S; Sauer R; Herbst M; Fietkau R; Flentje M; Miethe S; Boettcher HD; Scholten T; Bruns CJ; Rau HG; Hinke A; Heinemann V
Br J Cancer; 2009 Dec; 101(11):1853-9. PubMed ID: 19904268
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
Kachnic LA; Shaw JE; Manning MA; Lauve AD; Neifeld JP
Int J Cancer; 2001 Apr; 96(2):132-9. PubMed ID: 11291097
[TBL] [Abstract][Full Text] [Related]
14. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Reni M; Cereda S; Balzano G; Passoni P; Rognone A; Zerbi A; Nicoletti R; Mazza E; Arcidiacono PG; Di Carlo V; Villa E
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1253-9. PubMed ID: 19381632
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Combs SE; Habermehl D; Kessel KA; Bergmann F; Werner J; Naumann P; Jäger D; Büchler MW; Debus J
Ann Surg Oncol; 2014 Aug; 21(8):2801-7. PubMed ID: 24916745
[TBL] [Abstract][Full Text] [Related]
17. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG
Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO
Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Wilkowski R; Thoma M; Bruns C; Wagner A; Heinemann V
JOP; 2006 Jul; 7(4):349-60. PubMed ID: 16832132
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
Mattiucci GC; Boldrini L; Nardangeli A; D'Aviero A; Buwenge M; Cellini F; Deodato F; Dinapoli N; Frascino V; Macchia G; Morganti AG; Valentini V
J Cancer Res Clin Oncol; 2021 Mar; 147(3):661-667. PubMed ID: 33001271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]